Recruiting

Accuracy of Smartwatches in Measuring Oxygen Levels in Patients With Pulmonary Hypertension: A Pilot Study

ClinicalTrials.gov IDNCT07311135

PhaseNot Applicable

Enrollment20

SponsorGolden Jubilee National Hospital

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Pulmonary Hypertension

About this study

The goal of this study is to learn how accurate smartwatches are at measuring oxygen levels in patients with a condition called pulmonary hypertension. The main questions it aims to answer are: * How accurate the smartwatches are at measuring oxygen levels when the patient is sitting at rest * How accurate are smartwatches at measuring oxygen levels after exercise * How accurate are smartwatches at measuring oxygen levels after breathing a lower level of oxygen through a mask. Researchers will compare oxygen levels measured through a smartwatch with those checked through a finger probe oxygen monitor and also from a blood sample checked from the artery in the wrist to see if smartwatch oxygen measurements are similar. Participants will: -Attend the hospital once, just for a few hours to collect all the required data.

Primary outcomes

Agreement of oxygen saturations (SpO2) measured by the wrist-worn pulse oximeter when compared with arterial blood gas oxygen saturations (SaO2) at rest (1 study visit, anticipated to be around 3 hours.)

Eligibility information

Inclusion Criteria: * Aged 18-years old and above. * Diagnosed with pulmonary hypertension by right heart catheterisation showing a baseline mean pulmonary artery pressure \> 20mmHg, PVR \>2 Woods Units. * Able to perform a six-minute walk test (6MWT) * Able to give written informed consent. Exclusion Criteria: * Peripheral arterial disease * Tattoos or skin markings which cover the dorsal wrist. * Resting SpO2 \<88% * Severe concurrent medical condition that would prevent participation in study procedures or with life expectancy \<3 months * Patients with bleeding disorders * Patients on anticoagulation * Except in circumstances where anticoagulation is given solely for historical perceived long term survival benefit for pulmonary arterial hypertension. This patient group could be given the option to come off their anticoagulation for 1 week prior to the study visit if they wished to take part in the study. It could then be restarted the day following the study visit providing there were no bleeding complications related to the arterial line.

Study locations

Golden Jubilee National Hospital, Glasgow, G81 4DY United Kingdom

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.